Dr. Marta Wosinska, Director of Economics Staff at the FDA’s Center for Drug Evaluation and Research Over the past few years, a number of critically needed medicines have gone into short supply, adversely affecting patient care and disrupting clinical trials. A production disruption preceded virtually every such shortage. These disruptions are more likely to turn [...]
Toll Brothers is postponing a rise to investment grade by borrowing $1.7 billion to make an acquisition and refinance debt due next year. Click HERE for more.
Philadelphia wants to create its first blight-fighting district in eight years, financed by a type of municipal debt for which sales have dwindled to a fifth of the pre-recession pace. Click here to continue reading sample article.
Friday’s U.S. October nonfarm payrolls report will show major distortions due to the recent government shutdown and seasonal increases in state and local government hiring linked to education. The result will probably be a below-trend pace of hiring for the month and an increase in the unemployment rate. Click here to continue reading sample article.
The ECB will keep its policy rate at 0.5 percent for a sixth month today, a Bloomberg survey shows, even after inflation slowed to 0.7 percent in October. The bank on average makes a rate change at about 20 percent of its meetings. March and December have been the most popular months for changes, coinciding with the release [...]
Investors are demonstrating their eagerness to own dollar junk bonds by pushing yields to the least relative to high-grade debt since before the credit crisis. Click HERE for more.
Advancing the development of aviation biofuel should be a shared responsibility between airlines and various industry stakeholders – not one that should rest solely on the world’s airlines, said Jimmy Samartzis, United Continental Holdings’ managing director of global environmental affairs and sustainability. Click here to continue reading.
by Elizabeth Krutoholow As Roche’s top-selling leukemia treatment Rituxan nears its patent expiration, the drug maker is pushing to see its newer product, GA101, step into the spotlight. Approved by the FDA on Friday, GA101, also known as obinutuzumab, is a major part of Roche’s strategy to defend its franchise from biosimilar products. An embargo [...]
Special issue free download. We looked at who owns the largest U.S. SEC-registered structured notes, according to the most recent public filings. We examined the 1,000 biggest notes for each year from 2010 to 2013. We found $1.73 billion of declared holdings for 409 securities. The holdings in the table below are based on notional amounts of [...]